POST-TEST
Addressing Current Questions and Controversies in the Management of Non-Small Cell Lung Cancer with an EGFR Mutation (Faculty Presentations)
THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.
1. Which of the following disease-free 5. The investigational agent mobocertinib survival outcomes was reported in (TAK-788) has shown promising activity the Phase III ADAURA trial evaluating in the treatment of metastatic NSCLC osimertinib as adjuvant therapy for with which EGFR mutation? patients with Stage IB to Stage IIIA a. Exon 19 deletions non-small cell lung cancer (NSCLC) b. Exon 20 insertion mutations with EGFR mutations after complete c. Exon 21 mutations tumor resection? a. Statistically significant and clini- 6. Which of the following drug types best cally meaningful improvement describes the mechanism of action of versus placebo the novel agent patritumab deruxtecan b. Trend toward statistical significance (U3-1402)? versus placebo a. EGFR tyrosine kinase inhibitor c. No improvement versus placebo b. HER3-directed antibody-drug conjugate 2. Which of the following is a mechanism c. MET inhibitor of resistance to first-line osimertinib monotherapy in patients with NSCLC 7. The results of the Phase III FLAURA trial with EGFR mutations? evaluating osimertinib versus gefitinib a. MET amplification only or erlotinib for patients with untreated b. EGFR C797S mutation only advanced NSCLC with EGFR tumor c. Both MET amplification and EGFR mutations included which outcome with C797S mutation osimertinib? a. Longer PFS only 3. The ongoing Phase III FLAURA2 trial is b. Longer overall survival only investigating osimertinib with or without c. Longer PFS and overall survival chemotherapy for patients with locally advanced or metastatic NSCLC with 8. Which of the following drug types best EGFR mutations in which setting? describes the mechanism of action a. First-line therapy of the recently FDA-approved agent b. After 1 or more lines of therapy selpercatinib in patients with metastatic c. After 2 or more lines of therapy NSCLC? a. ALK inhibitor 4. Which progression-free survival (PFS) b. EGFR inhibitor result was reported from the Phase III c. HER2 inhibitor RELAY trial evaluating the EGFR tyrosine kinase inhibitor erlotinib alone or in d. MET inhibitor combination with the anti-angiogenic e. RET inhibitor agent ramucirumab for patients with f. ROS1 inhibitor previously untreated metastatic NSCLC with EGFR mutations? a. Ramucirumab/erlotinib was inferior to erlotinib alone b. Ramucirumab/erlotinib was similar to erlotinib alone c. Ramucirumab/erlotinib was superior to erlotinib alone
QID 3060 POST-TEST
Addressing Current Questions and Controversies in the Management of Non-Small Cell Lung Cancer with an EGFR Mutation (Faculty Presentations)
THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.
9. Emerging data evaluating the efficacy 10. Which of the following statements is of immune checkpoint inhibitors as true about osimertinib in comparison to single agents for NSCLC with EGFR or erlotinib? ALK alterations support which of the a. Osimertinib elicits a greater following observations? antitumor effect in the CNS a. Immune checkpoint inhibitors are b. Osimertinib causes more skin highly efficacious in patients with toxicity high PD-L1 expression c. Osimertinib has less antitumor b. Immune checkpoint inhibitors have efficacy low efficacy, even in patients with high PD-L1 expression
QID 3060